AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B
PR Newswire —
SAN FRANCISCO, Dec. 22, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing targeted oligonucleotide therapies for functional cure of chronic hepatitis B (CHB), today announced the...